Institution identification

Institution ID

3331270

Institution full name and acronym

Merck Sharp & Dohme LLC

Institution countries

United States

Type of institution

Pharmaceutical company

Institution role

Data provider

ENCePP partner

No
Institution description
No information provided.
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Contact

Studies conducted by the institution

A description of the management of invasive fungal infections with oral posaconazole maintenance treatment following intravenous antifungal regimens in routine UK clinical practice (MAINTAIN)
A description of the UK NHS hospital resource use and patient quality of life associated with hospitalisations for recurrent Clostridium difficile infection
A multi-center prospective non-interventional study to understand the use of next generation sequencing (NGS) in patients with metastatic non-small cell lung cancer and metastatic colorectal cancer in Belgium.
A national, multicenter, prospective, single-arm registry PASS of pulmonary hypertension patients treated with Riociguat (Adempas®) in China (MK-4836-001) (EXPERT China)
A Nested Case-control Post-authorization Safety Study of Etoricoxib and Other Non-steroidal Anti-inflammatory Therapies in a Cohort of Patients with Ankylosing Spondylitis (AS) in the UK, France and Germany (MK-0663-163)
A non-interventional, multicentre, prospective study to estimate the incidence of invasive fungal infections and to monitor the diagnostic and therapeutic management of suspected fungal-related febrile episodes in patients affected with hematological neoplasm (Hema e-Chart II) (MK-0991-803) (Hema E-Chart II)
A post-licensure prospective observational registry study in real-world Taiwanese cancer patients with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) genes
A Post-licensure Surveillance Program for the Safety of GARDASIL™ in a Managed Care Organization Setting (V501-031)
A Post-marketing Database Surveillance to Investigate the Risk of Hepatic Events in Hypercholesterolemic Patients Treated with ATOZET or Ezetimibe Atorvastatin coadministration in Japan (MK-0653C-853)
A Post-marketing Database Surveillance to Investigate the Risk of Hyperglycemia and Diabetes Mellitus in Hypercholesterolemic Patients Treated with ATOZET or Ezetimibe Atorvastatin coadministration in Japan (MK-0653C-855)
A Post-marketing Database Surveillance to Investigate the Risk of Rhabdomyolysis and Myopathy in Hypercholesterolemic Patients Treated with ATOZET or Ezetimibe Atorvastatin coadministration in Japan (MK-0653C-854)
A Post-Marketing Observational Study of Implanon® Radiopaque among Chinese Women Aged 18 and Older Requesting Contraception (MK-8415-038)
A Real-World Study on Pulmonary Arterial Hypertension in Bulgaria: A Single-Center Retrospective Study From 2012 to 2022
A study assessing the use of GOlimumab in current clinical PRACTICE and its impact on patients with chronic inflammatory arthritis (MK-8259-020) (GO-PRACTICE)
A Study of the Effectiveness and Safety of a New Formulation of RotaTeq™ in Routine Use in a Developing World Setting
Achieving Minimal Disease Activity and Predictors of clinical response in Patients with Psoriatic Arthritis treated with Golimumab in clinical practice: a Multicenter Observational Study (MK-8259-039)
An Observational Drug Utilization Study of SYCREST® (asenapine) in the United Kingdom (P08308)
An observational follow-up study for: a phase III randomized, placebo-controlled clinical trial to assess the safety and efficacy of odanacatib (MK-0822) to reduce the risk of fracture in osteoporotic postmenopausal women treated with vitamin D and calcium (Protocol 018) (MK-0822-083)
An Observational Post-Authorization Safety Study of Temodar® (Temozolomide) and Severe Acute Liver Injury in the HealthCore Integrated Research Environment (MK-7365-295)
An Observational Post-Authorization Safety Surveillance (PASS) Study of SYCREST® (asenapine) among Patients aged 18 and older Diagnosed with Bipolar Disorder (P08307)
An observational study to assess persistence on treatment, adherence, and patient-reported outcomes during the treatment of chronic hepatitis C genotype 1 infected patients with Boceprevir added to Peginterferon plus Ribavirin in Italy (MK-3034-137)
Association between use of desloratadine and risk of seizures, supraventricular tachycardia, and atrial fibrillation or flutter: A Nordic register-based study (MK-4117-205)
Building a pregnancy pharmacovigilance model for the future: Can pregnancy data collected by ConcePTION partners be analysed using common standards developed by the ConcePTION project?
Current raltegravir use: clinical practice in UK centres (CRICKET)
Etoricoxib Prescribing Patterns and Adverse Events of Interest during Etoricoxib Treatment in UK Primary Care (MK-0663-162)
GARDASIL(TM) Vaccine Impact in Population (VIP) Study (V501-033)
Nested case-control study evaluating effectiveness of immunization of girls and women of childbearing potential with GARDASIL(TM)/GARDASIL(TM) 9 against juvenile-onset recurrent respiratory papillomatosis (JoRRP) in Sweden, Denmark, and Norway (V503-095)
Non-interventional post-marketing safety study (PMSS) to collect information on hepatic function disorders among Japanese patients with radically unresectable or metastatic renal cell carcinoma treated with pembrolizumab in combination with axitinib (MK-3475-A97)
Observational Safety Data Analysis from Routine Follow-up in the EuroSIDA Study of Patients Treated with Raltegravir in a Five-Year Post Authorization Period (MK-0518-058)
Patients’, physicians', nurses’ and pharmacists’ preferences toward the attributes of biological agents used in the treatment of rheumatic diseases in Italy (MK-0000-330) (CARA)
Population-based retrospective nested case-control study evaluating effectiveness of GARDASIL™ /GARDASIL™9 against adult-onset recurrent respiratory papillomatosis (AoRRP) in Sweden, Denmark, and Norway (V503-088)
Post Marketing Active Surveillance to Evaluate the Safety and Efficacy of Aprepitant (EMEND®) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated with High Emetogenic Cancer Chemotherapy in China (MK-0869-804)
Post Marketing Surveillance of Effectiveness (All-Cause Mortality) of Posaconazole Injection and Tablet Treatment of Invasive Aspergillosis in Chinese patients (MK-5592-141)
Post-licensure Observational Safety Study of Gardasil 9 (V503-028)
Post-Licensure Observational Study of the Long-term Effectiveness of ZOSTAVAX(TM) (V211-024)
Post-Licensure Observational Study of the Safety of GARDASIL(TM) in Males (V501-070)
Post-Licensure Safety Study of ISENTRESS™ in a US Managed Care Network
Post-marketing Observational Study to Characterize the Safety and Effectiveness Profile of Orgalutran® in Chinese Women Undergoing Controlled Ovarian Hyperstimulation for Assisted Reproduction Techniques (MK-8761-050)
Post-marketing study to assess serotype-specific effectiveness of Reassortant Rotavirus Vaccine, Live, Oral, Pentavalent (Vero Cell) (ROTATEQ®) in China (V260-077)
Post-marketing study to assess the effectiveness of doravirine-included in highly active antiretroviral therapy (HAART) in HIV-1 infected adult Chinese patients (MK-1439-088)
Post-Marketing surveillance for HPV infection related serious disease in a cohort of Chinese women who received GARDASIL® and GARDASIL®9
Post-Marketing surveillance for the safety of GARDASIL® and GARDASIL®9 in a cohort of Chinese women
Post-marketing surveillance to monitor the incidence of intussusception after large-scale vaccination with Reassortant Rotavirus Vaccine, Live, Oral, Pentavalent (Vero Cell) (ROTATEQ®) in Chinese infants using the Ningbo Regional Health Information Platform (NRHIP)
Practicalities of Using Boceprevir and Early Responses to Treatment: Experience of the First Eighteen Months In the UK. The Boceprevir Real LIfe Treatment (BRIT) study
Real-world effectiveness of pembrolizumab among patients with TMB-H advanced solid tumors (MK-3475-G34)
Retrospective cohort study evaluating effectiveness of GARDASIL™ against adult-onset recurrent respiratory papillomatosis in Norway
Safety Data on Etoricoxib From Swedish Registries of Spondyloarthropathy/Ankylosing Spondylitis Patients (MK-0663-159; EP07013.013.11.082)
SGLT2 Inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: a Nested Case-control Study (MK-8835-067)
Study of Current Standard of Care in the U.S.: Incidence of postoperative events and associated costs among non-cardiac surgery patients exposed to neuromuscular blocking agents in the Cleveland Clinic (2005-2013)
The Risk of Esophageal Cancer in Relation to the Treatment and Prevention of Osteoporosis in Women (MK-0217A-352)
Use of benzodiazepines and risk of hip/femur fracture. A methodological comparison across data sources and epidemiological design.
Utilization of Ribavirin in Pediatric Patients with Hepatitis C Virus - Aggregated Experience of European Specialists (MK-8908-060)